endofocusFOCUS. EndocrinologyFOCUS Эндокринология2713-01772713-0185ООО "Издательство "Перо"10.62751/2713-0177-2026-7-2-05endofocus-207Research ArticleОБЗОРЫAutomated insulin delivery systems: An overview and current possibilitiesСистемы автоматизированного введения инсулина: обзор и современные возможностиhttps://orcid.org/0000-0002-7675-4496БаироваВ. Э.BairovaV. E.

Баирова Валерия Эдуардовна – ассистент кафедры эндокринологии ИКМ 

117997, г. Москва, ул. Островитянова, д. 1 

Valeriia E. Bairova – assistant at Department of endocrinology of the Institute of clinical medicine 

1 Ostrovityanova St., Moscow, 117997 

bairova.lera@mail.ruhttps://orcid.org/0000-0001-6385-540XДемидоваТ. Ю.MayarbievaT. T.

Демидова Татьяна Юльевна – д.м.н., профессор, заведующая кафедрой, заслуженный врач РФ 

Москва 

Tanzila T. Mayarbieva – assistant at Department of endocrinology of the Institute of clinical medicine 

Moscow 

t.y.demidova@gmail.comhttps://orcid.org/0009-0006-2826-4659МаярбиеваТ. Т.DemidovaT. Yu.

Маярбиева Танзила Тимерхановна – ассистент кафедры эндокринологии ИКМ 

Москва 

Tatyana Yu. Demidova – Dr. Sci (Med.), professor, Honored Doctor of the Russian Federation 

Moscow 

maarbievatanzila@gmail.comФедеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской ФедерацииРоссияPirogov Russian National Research Medical UniversityRussian FederationРоссийский национальный исследовательский медицинский университет имени Н.И. Пирогова (Пироговский университет)РоссияPirogov Russian National Research Medical UniversityRussian Federation202611072026724653Copyright © Bairova V.E., Mayarbieva T.T., Demidova T.Y., 20262026Баирова В.Э., Демидова Т.Ю., Маярбиева Т.Т.Bairova V.E., Mayarbieva T.T., Demidova T.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://endofocus.elpub.ru/jour/article/view/207

Currently, there is still a need to study and implement the most effective therapeutic approaches for patients with type 1 diabetes to reduce the risk of diabetes-related complications and improve quality of life. The development and integration of continuous glucose monitoring (CGM) systems and continuous subcutaneous insulin infusion have enabled the creation of more advanced systems that provide automated insulin delivery. These systems automatically adjust the insulin dose every few minutes based on CGM data, helping to achieve glycemic targets while significantly reducing the burden on the patient. This article provides an overview of the most popular automated insulin delivery systems, including open-source systems that have not yet received regulatory approval. The review emphasizes that, regardless of the type of device, clinical effectiveness largely depends on how successfully the patient masters the principles of insulin pump therapy and uses all the functions of the systems. Despite all the technological advances, the patient's active participation in managing insulin delivery currently remains essential. 

 В настоящее время все еще существует потребность в изучении и внедрении наиболее эффективных методов терапии пациентов с сахарным диабетом (СД) 1 типа c целью снижения риска осложнений заболевания и улучшения качества жизни. Развитие и интеграция систем непрерывного мониторирования гликемии (НМГ) и непрерывной подкожной инфузии инсулина позволила разработать более совершенные системы, обеспечивающие автоматизированную подачу инсулина. Они автоматически корректируют вводимую дозу инсулина каждые несколько минут, основываясь на показателях НМГ, что обеспечивает достижение целевых показателей гликемии, при этом значительно снижая нагрузку на пациента. В статье представлен обзор наиболее популярных систем автоматизированного введения инсулина, в том числе систем с открытым исходным кодом, не получивших на данный момент одобрения регулирующих органов. В обзоре подчеркивается, что вне зависимости от типа устройства его клиническая эффективность во многом зависит от успешности освоения пациентом принципов помповой инсулинотерапии и использования всех функций и возможностей систем. При всей технологичности в настоящее время, безусловно, все еще необходимо активное участие пациента в управлении любым способом введения инсулина. 

системы автоматизированного введения инсулинагибридные системы закрытого контуразакрытая петляоткрытый кодпомповая инсулинотерапияautomated insulin delivery systemshybrid closed-loop systemsclosed loopopen sourceinsulin pump therapyReferencesOgle GD, Wang F, Haynes A, Gregory GA, King TW, Deng K, et al. Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: Results from the International diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0. Diabetes Res Clin Pract. 2025;225:112277. https://doi.org/10.1016/j.diabres.2025.112277Ogle GD, Wang F, Haynes A, Gregory GA, King TW, Deng K, et al. Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: Results from the International diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0. Diabetes Res Clin Pract. 2025;225:112277. https://doi.org/10.1016/j.diabres.2025.112277Hankosky ER, Schapiro D, Gunn KB, Lubelczyk EB, Mitroi J, Nelson DR. Gaps remain for achieving HbA1c targets for people with type 1 or type 2 diabetes using insulin: Results from NHANES 2009–2020. Diabetes Ther. 2023;14(6):967–75. https://doi.org/10.1007/s13300-023-01399-0Hankosky ER, Schapiro D, Gunn KB, Lubelczyk EB, Mitroi J, Nelson DR. Gaps remain for achieving HbA1c targets for people with type 1 or type 2 diabetes using insulin: Results from NHANES 2009–2020. Diabetes Ther. 2023;14(6):967–75. https://doi.org/10.1007/s13300-023-01399-0Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В. Исаков М.А., Сазонова Д.В., Мокрышева Н.Г. Сахарный диабет в Российской Федерации: динамика эпидемиологических показателей по данным Федерального регистра сахарного диабета за период 2010–2022 гг. Сахарный диабет. 2023;26(2):104–123. https://doi.org/10.14341/DM13035Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MA, Sazonova DV, Mokrysheva NG. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Sakharnyy diabet = Diabetes mellitus. 2023;26(2):104–123 (In Russ.). https://doi.org/10.14341/DM13035Berget C, Messer LH, Forlenza GP. A clinical overview of insulin pump therapy for the management of diabetes: Past, present, and future of intensive therapy. Diabetes Spectr. 2019;32(3):194–204. https://doi.org/10.2337/ds18-0091Berget C, Messer LH, Forlenza GP. A clinical overview of insulin pump therapy for the management of diabetes: Past, present, and future of intensive therapy. Diabetes Spectr. 2019;32(3):194–204. https://doi.org/10.2337/ds18-0091Ambalavanan J, Isaacs D, Lansang MC. Diabetes technology: A primer for clinicians. Cleve Clin J Med. 2024;91(6):353–60. https://doi.org/10.3949/ccjm.91a.23073Ambalavanan J, Isaacs D, Lansang MC. Diabetes technology: A primer for clinicians. Cleve Clin J Med. 2024;91(6):353–60. https://doi.org/10.3949/ccjm.91a.23073Marshall DC, Holloway M, Korer M, Woodman J, Brackenridge A, Hussain S. Do-It-Yourself artificial pancreas systems in type 1 diabetes: Perspectives of two adult users, a caregiver and three physicians. Diabetes Ther. 2019;10(5):1553–64. https://doi.org/10.1007/s13300-019-00679-yMarshall DC, Holloway M, Korer M, Woodman J, Brackenridge A, Hussain S. Do-It-Yourself artificial pancreas systems in type 1 diabetes: Perspectives of two adult users, a caregiver and three physicians. Diabetes Ther. 2019;10(5):1553–64. https://doi.org/10.1007/s13300-019-00679-yPeacock S, Frizelle I, Hussain S. A systematic review of commercial hybrid closedloop automated insulin delivery systems. Diabetes Ther. 2023;14(5):839–55. https://doi.org/10.1007/s13300-023-01394-5Peacock S, Frizelle I, Hussain S. A systematic review of commercial hybrid closedloop automated insulin delivery systems. Diabetes Ther. 2023;14(5):839–55. https://doi.org/10.1007/s13300-023-01394-5Castellanos LE, Balliro CA, Sherwood JS, Jafri R, Hillard MA, Greaux E, et al. Performance of the insulin-only iLet bionic pancreas and the bihormonal iLet using dasiglucagon in adults with type 1 diabetes in a home-use setting. Diabetes Care. 2021;44(6):e118–e120. https://doi.org/10.2337/dc20-1086Castellanos LE, Balliro CA, Sherwood JS, Jafri R, Hillard MA, Greaux E, et al. Performance of the insulin-only iLet bionic pancreas and the bihormonal iLet using dasiglucagon in adults with type 1 diabetes in a home-use setting. Diabetes Care. 2021;44(6):e118–e120. https://doi.org/10.2337/dc20-1086Haidar A, Tsoukas MA, Bernier-Twardy S, Yale JF, Rutkowski J, Bossy A, et al. A novel dual-hormone insulin-and-pramlintide artificial pancreas for type 1 diabetes: A randomized controlled crossover trial. Diabetes Care. 2020;43(3):597–606. https://doi.org/10.2337/dc19-1922Haidar A, Tsoukas MA, Bernier-Twardy S, Yale JF, Rutkowski J, Bossy A, et al. A novel dual-hormone insulin-and-pramlintide artificial pancreas for type 1 diabetes: A randomized controlled crossover trial. Diabetes Care. 2020;43(3):597–606. https://doi.org/10.2337/dc19-1922El Youssef J, Castle J, Ward WK. A review of closed-loop algorithms for glycemic control in the treatment of type 1 diabetes. Algorithms. 2009; 2(1):518–32. https://doi.org/10.3390/a2010518El Youssef J, Castle J, Ward WK. A review of closed-loop algorithms for glycemic control in the treatment of type 1 diabetes. Algorithms. 2009; 2(1):518–32. https://doi.org/10.3390/a2010518Fan W, Deng C, Xu R, Liu Z, Leslie RD, Zhou Z, Li X. Efficacy and safety of automated insulin delivery systems in patients with type 1 diabetes mellitus: A systematic review and meta-analysis. Diabetes Metab J. 2025;49(2):235–51. https://doi.org/10.4093/dmj.2024.0130Fan W, Deng C, Xu R, Liu Z, Leslie RD, Zhou Z, Li X. Efficacy and safety of automated insulin delivery systems in patients with type 1 diabetes mellitus: A systematic review and meta-analysis. Diabetes Metab J. 2025;49(2):235–51. https://doi.org/10.4093/dmj.2024.0130Choudhary P, Arrieta A, van den Heuvel T, Castaneda J, Smaniotto V, Cohen O. Celebrating the data from 100,000 real-world users of the MiniMed™ 780G system in Europe, Middle East, and Africa collected over 3 years: From data to clinical evidence. Diabetes Technol Ther. 2024;26(S3):32–37. https://doi.org/10.1089/dia.2023.0433Choudhary P, Arrieta A, van den Heuvel T, Castaneda J, Smaniotto V, Cohen O. Celebrating the data from 100,000 real-world users of the MiniMed™ 780G system in Europe, Middle East, and Africa collected over 3 years: From data to clinical evidence. Diabetes Technol Ther. 2024;26(S3):32–37. https://doi.org/10.1089/dia.2023.0433De Meulemeester J, Keymeulen B, De Block C, Van Huffel L, Taes Y, Ballaux D, et al. One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: A prospective observational cohort study. Diabetologia. 2025;68(5):948–60. https://doi.org/10.1007/s00125-025-06366-xDe Meulemeester J, Keymeulen B, De Block C, Van Huffel L, Taes Y, Ballaux D, et al. One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: A prospective observational cohort study. Diabetologia. 2025;68(5):948–60. https://doi.org/10.1007/s00125-025-06366-xBenhalima K, Jendle J, Beunen K, Ringholm L. Automated insulin delivery for pregnant women with type 1 diabetes: Where do we stand? J Diabetes Sci Technol. 2024;18(6):1334–45. https://doi.org/10.1177/19322968231223934Benhalima K, Jendle J, Beunen K, Ringholm L. Automated insulin delivery for pregnant women with type 1 diabetes: Where do we stand? J Diabetes Sci Technol. 2024;18(6):1334–45. https://doi.org/10.1177/19322968231223934Alwan H, Wilinska ME, Ruan Y, Da Silva J, Hovorka R. Real-world evidence analysis of a hybrid closed-loop system. J Diabetes Sci Technol. 2025;19(2):385–89. https://doi.org/10.1177/19322968231185348Alwan H, Wilinska ME, Ruan Y, Da Silva J, Hovorka R. Real-world evidence analysis of a hybrid closed-loop system. J Diabetes Sci Technol. 2025;19(2):385–89. https://doi.org/10.1177/19322968231185348Benhamou PY, Adenis A, Lebbad H, Tourki Y, Heredia MB, Gehr B, et al. One-year real-world performance of the DBLG1 closed-loop system: Data from 3706 adult users with type 1 diabetes in Germany. Diabetes Obes Metab. 2023;25(6):1607–13. https://doi.org/10.1111/dom.15008Benhamou PY, Adenis A, Lebbad H, Tourki Y, Heredia MB, Gehr B, et al. One-year real-world performance of the DBLG1 closed-loop system: Data from 3706 adult users with type 1 diabetes in Germany. Diabetes Obes Metab. 2023;25(6):1607–13. https://doi.org/10.1111/dom.15008Cobry EC, Berget C, Messer LH, Forlenza GP. Review of the Omnipod® 5 automated glucose control system powered by Horizon™ for the treatment of type 1 diabetes. Ther Deliv. 2020;11(8):507–19. https://doi.org/10.4155/tde-2020-0055Cobry EC, Berget C, Messer LH, Forlenza GP. Review of the Omnipod® 5 automated glucose control system powered by Horizon™ for the treatment of type 1 diabetes. Ther Deliv. 2020;11(8):507–19. https://doi.org/10.4155/tde-2020-0055Brown SA, Forlenza GP, Bode BW, Pinsker JE, Levy CJ, Criego AB, et al.; Omnipod 5 Research Group. Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care. 2021;44(7):1630–40. https://doi.org/10.2337/dc21-0172Brown SA, Forlenza GP, Bode BW, Pinsker JE, Levy CJ, Criego AB, et al.; Omnipod 5 Research Group. Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care. 2021;44(7):1630–40. https://doi.org/10.2337/dc21-0172Di Molfetta S, Di Gioia L, Caruso I, Cignarelli A, Green SC, Natale P, et al. Efficacy and safety of different hybrid closed loop systems for automated insulin delivery in people with type 1 diabetes: A systematic review and network meta-analysis. Diabetes Metab Res Rev. 2024;40(6):e3842. https://doi.org/10.1002/dmrr.3842Di Molfetta S, Di Gioia L, Caruso I, Cignarelli A, Green SC, Natale P, et al. Efficacy and safety of different hybrid closed loop systems for automated insulin delivery in people with type 1 diabetes: A systematic review and network meta-analysis. Diabetes Metab Res Rev. 2024;40(6):e3842. https://doi.org/10.1002/dmrr.3842Godoi A, Reis Marques I, Padrao EMH, Mahesh A, Hespanhol LC, Riceto Loyola Junior JE et al. Glucose control and psychosocial outcomes with use of automated insulin delivery for 12 to 96 weeks in type 1 diabetes: A meta-analysis of randomised controlled trials. Diabetol Metab Syndr. 2023;15(1):190. https://doi.org/10.1186/s13098-023-01144-4Godoi A, Reis Marques I, Padrao EMH, Mahesh A, Hespanhol LC, Riceto Loyola Junior JE et al. Glucose control and psychosocial outcomes with use of automated insulin delivery for 12 to 96 weeks in type 1 diabetes: A meta-analysis of randomised controlled trials. Diabetol Metab Syndr. 2023;15(1):190. https://doi.org/10.1186/s13098-023-01144-4Garg SK, McVean JJ. Development and future of automated insulin delivery (AID) systems. Diabetes Technol Ther. 2024;26(S3):1–6. https://doi.org/10.1089/dia.2023.0467Garg SK, McVean JJ. Development and future of automated insulin delivery (AID) systems. Diabetes Technol Ther. 2024;26(S3):1–6. https://doi.org/10.1089/dia.2023.0467Jansky B, Langstrup H. Device activism and material participation in healthcare: retracing forms of engagement in the -WeAreNotWaiting movement for opensource closed-loop systems in type 1 diabetes self-care. Biosocieties. 2022:1–25. Online ahead of print. https://doi.org/10.1057/s41292-022-00278-4Jansky B, Langstrup H. Device activism and material participation in healthcare: retracing forms of engagement in the -WeAreNotWaiting movement for opensource closed-loop systems in type 1 diabetes self-care. Biosocieties. 2022:1–25. Online ahead of print. https://doi.org/10.1057/s41292-022-00278-4Lewis D. History and perspective on DIY closed looping. J Diabetes Sci Technol. 2019;13(4):790–93. https://doi.org/10.1177/1932296818808307Lewis D. History and perspective on DIY closed looping. J Diabetes Sci Technol. 2019;13(4):790–93. https://doi.org/10.1177/1932296818808307Шишин К.С., Климонтов В.В. Системы автоматизированного введения инсулина с открытым кодом: преимущества, ограничения и вызовы в лечении сахарного диабета. Сахарный диабет. 2023;26(4):352–362. [Shishin KS, Klimontov VV. Open source automated insulin delivery systems: Benefits, limitations and challenges in diabetes care. Sakharnyy diabet = Diabetes mellitus. 2023;26(4):352–362 (In Russ.)]. https://doi.org/10.14341/DM13022Shishin KS, Klimontov VV. Open source automated insulin delivery systems: Benefits, limitations and challenges in diabetes care. Sakharnyy diabet = Diabetes mellitus. 2023;26(4):352–362 (In Russ.). https://doi.org/10.14341/DM13022Wang Q, Li X, Zhang W, Wang H, Tang J, Ding Y, et al. Effectiveness of opensource Android artificial pancreas systems for glucose management in patients with type 1 diabetes: A real-world study. Ther Adv Endocrinol Metab. 2025;16:20420188251350210. https://doi.org/10.1177/20420188251350210Wang Q, Li X, Zhang W, Wang H, Tang J, Ding Y, et al. Effectiveness of opensource Android artificial pancreas systems for glucose management in patients with type 1 diabetes: A real-world study. Ther Adv Endocrinol Metab. 2025;16:20420188251350210. https://doi.org/10.1177/20420188251350210Samuel P, Khan N, Klein G, Skobkarev S, Mammon B, Fournier M, et al. Opensource artificial pancreas systems are safe and effective when supported in-clinic: Outcomes in 248 consecutive type 1 diabetes clients. Can J Diabetes. 2024;48(1):59–65.e1. https://doi.org/10.1016/j.jcjd.2023.09.003Samuel P, Khan N, Klein G, Skobkarev S, Mammon B, Fournier M, et al. Opensource artificial pancreas systems are safe and effective when supported in-clinic: Outcomes in 248 consecutive type 1 diabetes clients. Can J Diabetes. 2024;48(1):59–65.e1. https://doi.org/10.1016/j.jcjd.2023.09.003Климонтов В.В., Шишин К.С. Системы автоматизированного введения инсулина с открытым кодом: опыт российских пациентов. Сахарный диабет. 2023;26(6):615–618. https://doi.org/10.14341/DM13033Klimontov VV, Shishin KS. Open source automated insulin delivery systems: Experience of russian patients. Sakharnyy diabet = Diabetes mellitus. 2023;26(6):615–618 (In Russ.). https://doi.org/10.14341/DM13033

The authors declare that there are no conflicts of interest present.